Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1/2 1

Status

Completed 23Recruiting 7Terminated 5Unknown 3Not yet recruiting 3Withdrawn 2Active not recruiting 2

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Breast 2Tumor-Agnostic 1Other hematologic neoplasm 1Lymphoid 1Gynecologic 1CNS 1

Conditions

Breast Neoplasms 2

Interventions

Paclitaxel 83Fulvestrant 65Trastuzumab 62Letrozole 61pembrolizumab 53Carboplatin 51Cyclophosphamide 48pertuzumab 46palbociclib 44Anastrozole 41Capecitabine 33Tamoxifen 30Magnetic Resonance Spectroscopy 29exemestane 28Radiotherapy 28Doxorubicin 28ribociclib 26olaparib 26Docetaxel 26Specimen Handling 25abemaciclib 24130-nm albumin-bound paclitaxel 20trastuzumab deruxtecan 19Taxes 19Gemcitabine 19durvalumab 18Surveys and Questionnaires 18Epirubicin 18eribulin 17Alpelisib 17

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Active not recruiting × neratinib × Breast × Clear all
NCT03377387 2026-04-16

Capecitabine 7/7 Schedule With Neratinib in Patients With Metastatic HER2-Positive Breast Cancer

Memorial Sloan Kettering Cancer Center

Phase 1/2 Active not recruiting
34 enrolled
Breast

Breast Neoplasms

NCT05252988 2025-04-01

DIANER

Spanish Breast Cancer Research Group

Phase 2 Active not recruiting
177 enrolled
Breast

Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡